NEW YORK (GenomeWeb) – Investment bank Leerink Partners today said it has downgraded Bruker's stock to Market Perform from Outperform based on expectations that margin expansion will be more difficult than is indicated by the current stock price.

Bruker's stock has appreciated 55 percent in the past year compared to no appreciation for the S&P 500, wrote Leerink analyst Dan Leonard in his note today. Leerink believes "the large, discrete activities for margin expansion are in the rear view mirror," he added.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.